

Announcement No. 19/2009
To NASDAQ OMX Copenhagen

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

9 November 2009

Exiqon appoints Mark R. Willig as Chief Commercial Officer

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the appointment of Mark R. Willig as new Chief Commercial Officer.

Mark Willig joins Exiqon from Thermo Fisher Scientific, Inc. where he held a position as Vice President of Global Sales since 2007 serving customers within the pharmaceutical and biotech industry, hospitals, clinical laboratories, research institutions and government agencies.

Prior to Thermo Fisher Scientific, Inc., Mark has served in various senior management positions at Prognostix, Inc., Specialty Labs, Inc., Myriad Genetics, Inc. and Orca Medical Systems, Inc. Mark brings more than 20 years of sales and marketing experience.

Mark Willig will be responsible for managing sales & marketing of all products and services in both of Exiqon's two financial segments: Exiqon Diagnostics and Exiqon Life Sciences. Mark Willig replaces Erik Holmlin.

Lars Kongsbak, President and CEO says: "Mark brings to Exiqon important sales management skills and experience with the markets in which we operate. We are excited to have him join our team and support our continued efforts to establish Exiqon as a market leader for miRNA diagnostics and miRNA research based on our proprietary LNA™ detection technology".

Additional information

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon operates in two business segments sharing one vision: the idea of taking science to patients through personalized medicine; one focus: the promise of miRNA as biological markers; and one technology platform: our proprietary LNA™ (Locked Nucleic Acid) detection technology with its unique competitive advantages in the markets we address. Exiqon Life Sciences has established a position for itself as one of the market's leading providers of research products for gene expression analysis. Our products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries in the field of gene expression analysis. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biological markers (Pharma Services). Exiqon Diagnostics is a leading provider of cellular based diagnostics for cancer treatment selection. We are developing a series of new molecular diagnostic tests for high incidence cancers based on miRNA biomarkers. The first test has been developed, and additional tests are in the pipeline for each coming year. Exiqon has approximately 170 employees and is listed on the NASDAQ OMX in Copenhagen. For more information about Exiqon, visit www.exiqon.com.

